The pathogenesis and prevention of encephalitis due to human enterovirus 71

Current Infectious Disease Reports

Volumn 14, Issue 4, 2012, Pages 397-407

  Bek, Emily Jane ^a   McMinn, Peter Charles ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Hand foot and mouth disease (HFMD); Human enterovirus 71 (HEV71); Picornavirus; Viral encephalitis

Indexed keywords

INACTIVATED VIRUS VACCINE; INTERFERON; LIVE VACCINE; PEPTIDE VACCINE; RIBAVIRIN; RUPINTRIVIR; VIRUS LIKE PARTICLE VACCINE; VIRUS PROTEIN;

ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DISEASE SURVEILLANCE; ENCEPHALITIS; ENTEROVIRUS 71; GENOTYPE; HUMAN; IMMUNE EVASION; INFECTION CONTROL; NONHUMAN; PATHOGENESIS; PROTEIN PROCESSING; VACCINATION; VIRION; VIRUS CAPSID; VIRUS ENTRY; VIRUS GENE; VIRUS GENOME; VIRUS RELEASE; VIRUS REPLICATION; VIRUS TRANSCRIPTION; VIRUS VIRULENCE;

EID: 84865640023     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0267-3     Document Type: Article

References (151)

1. McMinn P. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26(1):91-107. (Pubitemid 34454778)
2. Xu W, Liu C-F, Yan L, et al. Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J. 2012;9(1):8. 3. 9.
3. Bek EJ, Hussain KM, Phuektes P, et al. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine. 2011;29(29-30):4829-38. This study reports complete cross-protection between genotypes of HEV71 in a passive protection mosue model conferred by an inactivated HEV71 vaccine.
4. Ansardi DC, Porter DC, Anderson MJ, Morrow CD. Poliovirus assembly and encapsidation of genomic RNA. In: KarlMaramorosch FAM, Aaron JS, editors. Advances in virus research. Academic Press; 1996. p. 1-68.
5. Chua K, Kasri A. Hand foot and mouth disease due to enterovirus 71 in Malaysia. Virol Sin. 2011;26(4):221-8.
6. Wang SM, Ho TS, Lin HC, et al. Reemerging of enterovirus 71 in Taiwan: The age impact on disease severity. European journal of clinical microbiology & infectious diseases: Official publication of the European Society of Clinical Microbiology, 2011.
7. Tan X, Huang X, Zhu S, et al. The persistent circulation of enterovirus 71 in people's republic of china: Causing emerging nationwide epidemics since 2008. PLoS One. 2011;6(9):e25662.
8. Mao Q, Li N, Yu X, et al. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol. 2012;157(1):37-41.
9. Yang F, Zhang T, Hu Y, et al. Survey of enterovirus infections from hand, foot and mouth disease outbreak in china, 2009. Virol J. 2011;8(1):508.
10. Bek EJ, McMinn PC. Recent advances in research on human enterovirus 71. Futur Virol. 2010;5(4):453-68.
11. Puenpa J, Theamboonlers A, Korkong S, et al. Molecular characterization and complete genome analysis of human enterovirus 71 and coxsackievirus A16 from children with hand, foot and mouth disease in Thailand during 2008-2011. Arch Virol. 2011;156(11):2007-13.
12. Schuffenecker I, Mirand A, Antona D, et al. Epidemiology of human enterovirus 71 infections in France, 2000-2009. J Clin Virol. 2011;50(1):50-6.
13. Ang L-W, Phoon M-C, Wu Y, et al. The changing seroepidemiology of enterovirus 71 infection among children and adolescents in Singapore. BMC Infect Dis. 2011;11(1):270.
14. Kadurugamuwa JL, Shaheen E. Inactivation of human enterovirus 71 and coxsackie virus A16 and hand, foot, and mouth disease. Am J Infect Control. 2011;39(9):788-9.
15. Tu PV, Thao NTT, Perera D, et al. Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis. 2007;13(11):1733-41. (Pubitemid 350126202)
16. Surveillance of hand, foot and mouth disease in Singapore. Epidemiol News Bull. 2000:3-5.
17. Wu TN, Tsai SF, Li SF, et al. Sentinel surveillance for enterovirus 71, Taiwan, 1998. Emerg Infect Dis. 1999;5(3):458-60.
18. Tee KK, Lam TT-Y, Chan YF, et al. Evolutionary genetics of human enterovirus 71: Origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol. 2010;84(7):3339-50. This paper is an excellent up-To-date review of HEV71 epidemiology and analysis of recent evidence of recombination.
19. Zhang Y, Wang J, Guo W, et al. Emergence and transmission pathways of rapidly evolving evolutionary branch C4a strains of human enterovirus 71 in the central plain of China. PLoS One. 2011;6(11):e27895.
20. Choi CS, Choi YJ, Choi UY, et al. Clinical manifestations of CNS infections caused by enterovirus type 71. Korean J Pediatr. 2011;54(1):11-6.
21. Huang S-W, Hsu Y-W, Smith DJ, et al. Reemergence of enterovirus 71 in 2008 in Taiwan: Dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Microbiol. 2009;47 (11):3653-62.
22. Solomon TA, Willison HB. Infectious causes of acute flaccid paralysis. Curr Opin Infect Dis. 2003;16(5):375-81.
23. Huang S-W, Kiang D, Smith DJ, Wang J-R. Evolution of reemergent virus and its impact on enterovirus 71 epidemics. Exp Biol Med. 2011;236(8):899-908.
24. Yan X-F, Gao S, Xia J-F, et al. Epidemic characteristics of hand, foot, and mouth disease in Shanghai from 2009 to 2010: Enterovirus 71 subgenotype C4 as the primary causative agent and a high incidence of mixed infections with coxsackievirus A16. Scand J Infect Dis. 2011, Epub ahead of print:1-9.
25. van der Sanden S, van Eek J, Martin DP, et al. Detection of recombination breakpoints in the genomes of human enterovirus 71 strains isolated in the Netherlands in epidemic and nonepidemic years, 1963-2010. Infect Genet Evol. 2011;11(5):886-94.
26. McWilliam Leitch EC, Cabrerizo M, Cardosa J, et al. The association of recombination events in the founding and emergence of subgenogroup evolutionary lineages of human enterovirus 71. J Virol. 2011;86(5):2676-85. This paper provides compelling evidence of the role of recombination events in the evolution of new epidemic strains of HEV71.
27. Chen X, Zhang Q, Li J, et al. Analysis of recombination and natural selection in human enterovirus 71. Virology. 2010;398 (2):251-61.
28. Yoke-Fun C, AbuBakar S. Phylogenetic evidence for inter-Typic recombination in the emergence of human enterovirus 71 subgenotypes. BMC Microbiol. 2006;6(1):74.
29. Yip C, Lau S, Zhou B, et al. Emergence of enterovirus 71 "double-recombinant" strains belonging to a novel genotype D originating from southern China: First evidence for combination of intratypic and intertypic recombination events in EV71. Arch Virol. 2010;155(9):1413-24.
30. Chen G-W, Hsiung C, Chyn J-L, et al. Revealing molecular targets for enterovirus type 71 detection by profile hidden markov models. Virus Genes. 2005;31(3):337-47. (Pubitemid 41374378)
31. Bible JM, Iturriza-Gomara M, Megson B, et al. Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J Clin Microbiol. 2008;46(10):3192-200.
32. Ooi MH, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9 (11):1097-105.
33. Gong J. Risk factors for fatal cases with hand-foot-mouth disease (HFMD) in Guangxi, China. Pediatr Res. 2011;70(S5):445.
34. World Health Organization. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). Geneva: WHO Press, World Health Organization; 2011. This is a comprehensive guide developed by the WHO that provides standardized case definitions and guidelines for clinical management of severe cases of EV71-Associated HFMD. It also provides an excellent review of epidemiology, virology, diagnosis, pathogenesis and prevention of HEV71.
35. Witsø E, Palacios G, Rønningen KS, et al. Asymptomatic circulation of HEV71 in Norway. Virus Res. 2007;123(1):19-29. (Pubitemid 44751913)
36. Badran SA, Midgley S, Andersen P, Ttiger B. Clinical and virological features of enterovirus 71 infections in Denmark, 2005 to 2008. Scand J Infect Dis. 2011;43(8):642-8.
37. Pérez-Vélez CM, Anderson MS, Robinson CC, et al. Outbreak of neurologic enterovirus type 71 disease: A diagnostic challenge. Clin Infect Dis. 2007;45(8):950-7. (Pubitemid 47580341)
38. Siafakas N, Attilakos A, Vourli S, et al. Molecular detection and identification of enteroviruses in children admitted to a university hospital in Greece. Mol Cell Probes. 2011;25(5-6):249-54.
39. Ooi MH, Wong SC, Podin Y, et al. Human enterovirus 71 disease in Sarawak, Malaysia: A prospective clinical, virological, and molecular epidemiological study. Clin Infect Dis. 2007;44 (5):646-56.
40. Zeng H, Wen F, Gan Y, Huang W. MRI and associated clinical characteristics of EV71-induced brainstem encephalitis in children with hand-foot-mouth disease. Neuroradiol. 2011, Epub ahead of print:1-8.
41. Huang F-L, Chen C-H, Huang S-K, Chen P-Y. An outbreak of enterovirus 71 in a nursery. Scand J Infect Dis. 2010;42:609-12.
42. Chang L-Y, Huang L-M, Gau SS-F, et al. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med. 2007;356(12):1226-34. (Pubitemid 46465598)
43. Huang C-C, Liu C-C, Chang Y-C, et al. Neurologic complications in children with enterovirus 71 infection. N Engl J Med. 1999;341(13):936-42. (Pubitemid 29441547)
44. Chen CY, Chang YC, Huang CC, et al. Acute flaccid paralysis in infants and young children with enterovirus 71 infection: MR imaging findings and clinical correlates. Am J Neuroradiol. 2001;22(1):200-5.
45. Shen WC, Tsai CH, Chiu HH, Chow KC. MRI of Enterovirus 71 myelitis with monoplegia. Neuroradiology. 2000;42(2):124-7. (Pubitemid 30122091)
46. Li J, Chen F, Liu T, Wang L. MRI findings of neurological complications in hand-foot-mouth disease by enterovirus 71 infection. Int J Neurosci. 2012, Feb 20 (Epub ahead of print).
47. Wong KT, Munisamy B, Ong KC, et al. The distribution of inflammation and virus in human enterovirus 71 encephalomyelitis suggests possible viral spread by neural pathways. J Neuropathol Exp Neurol. 2008;67(2):162-9. doi:10.1097/nen.0b013e318163a990
48. Shieh WJ, Jung SM, Hsueh C, et al. Pathologic studies of fatal cases in outbreak of hand, foot, and mouth disease, Taiwan. Emerg Infect Dis. 2001;7(1):146-8. (Pubitemid 32173346)
49. Sabin AB. Paralytic poliomyelitis: Old dogmas and new perspectives. Rev Infect Dis. 1981;3(3):543-64.
50. Wang S-M, Liu C-C, Tseng H-W, et al. Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis. 1999;29 (1):184-90. (Pubitemid 29336822)
51. Yan J-J, Wang J-R, Liu C-C, et al. An outbreak of enterovirus 71 infection in Taiwan 1998: A comprehensive pathological, virological, and molecular study on a case of fulminant encephalitis. J Clin Virol. 2000;17(1):13-22. (Pubitemid 30256287)
52. Huang M-C,Wang S-M, Hsu Y-W, et al. Long-Term cognitive and motor deficits after enterovirus 71 brainstem encephalitis in children. Pediatrics. 2006;118(6):e1785-8. (Pubitemid 46397554)
53. Chang LY, Lin TY, Hsu KH, et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet. 1999;354(9191):1682-6.
54. McMinn P, Stratov I, Nagarajan L, Davis S. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis. 2001;32(2):236-42. (Pubitemid 32524793)
55. Ng DKK, Law AKW, Cherk SWW, Mak KL. First fatal case of enterovirus 71 infection in Hong Kong. Hong Kong Med J. 2001;7(2):193-6. (Pubitemid 32772470)
56. Xie J, Jiao Y, Qiu Z, et al. Significant elevation of B cells at the acute stage in enterovirus 71-infected children with central nervous system involvement. Scand J Infect Dis. 2010;42(11-12):931-5.
57. Nagata N, Iwasaki T, Ami Y, et al. Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol. 2004;85(10):2981-9. (Pubitemid 39360042)
58. Tsou Y-A, Cheng Y-K, Chung H-K, et al. Upper aerodigestive tract sequelae in severe enterovirus 71 infection: Predictors and outcome. Int J Pediatr Otorhinolaryngol. 2008;72 (1):41-7. (Pubitemid 350198651)
59. van der Sanden S, Koopmans M, Uslu G, et al. Epidemiology of enterovirus 71 in the Netherlands, 1963 to 2008. J Clin Microbiol. 2009;47(9):2826-33.
60. Ahmed R, Buckland M, Davies L, et al. Enterovirus 71 meningoencephalitis complicating rituximab therapy. J Neurol Sci. 2011;305(1-2):149-51.
61. Patel KP, Bergelson JM. Receptors identified for hand, foot and mouth virus. Nat Med. 2009;15(7):728-9. 62. 9.
62. Yamayoshi S, Yamashita Y, Li J, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;15(7):798-801. This is the first description of the role of SCARB2 as the human cellular receptor for HEV71.
63. Yamayoshi S, Koike S. Identification of a human SCARB2 region that is important for enterovirus 71 binding and infection. J Virol. 2011;85(10):4937-46. 64. 9.
64. Chen P, Song Z, Qi Y, et al. Molecular determinants of enterovirus 71 viral entry. J Biol Chem. 2012;287(9):6406-20. This paper provides the most convincing evidence to date that SCARB2 is a key receptor for HEV71.
65. Lin Y-W, Lin H-Y, Tsou Y-L, et al. Human SCARB2-mediated entry and endocytosis of EV71. PLoS One. 2012;7(1):e30507.
66. Nishimura Y, Shimojima M, Tano Y, et al. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009;15(7):794-7.
67. Liu J, Dong W, Quan X, et al. Transgenic expression of human Pselectin glycoprotein ligand-1 is not sufficient for enterovirus 71 infection in mice. Arch Virol. 2012;157(3):539-43.
68. Miyamura K, Nishimura Y, Abo M, et al. Adaptive mutations in the genomes of enterovirus 71 strains following infection of mouse cells expressing human P-selectin glycoprotein ligand-1. J Gen Virol. 2011;92(2):287-91.
69. Chua BH, Phuektes P, Sanders SA, et al. The molecular basis of mouse adaptation by human enterovirus 71. J Gen Virol. 2008;89 (7):1622-32.
70. Zaini Z, Phuektes P, McMinn P. A reverse genetic study of the adaptation of human enterovirus 71 to growth in Chinese hamster ovary cells. Virus Res. 2012;163:doi:10.1016/j.virusres.2012.02.009
71. Huang S-W, Wang Y-F, Yu C-K, et al. Mutations in VP2 and VP1 capsid proteins increase infectivity and mouse lethality of enterovirus 71 by virus binding and RNA accumulation enhancement. Virology. 2012;422(1):132-43.
72. Ohba K, Ryo A, Dewan MZ, et al. Follicular dendritic cells activate HIV-1 replication in monocytes/macrophages through a juxtacrine mechanism mediated by P-selectin glycoprotein ligand 1. J Immunol. 2009;183(1):524-32.
73. Klopocki AG, Yago T, Mehta P, et al. Replacing a lectin domain residue in L-selectin enhances binding to P-selectin glycoprotein ligand-1 but not to 6-sulfo-sialyl lewis x. J Biol Chem. 2008;283 (17):11493-500.
74. Lin Y-W, Wang S-W, Tung Y-Y, Chen S-H. Enterovirus 71 infection of human dendritic cells. Exp Biol Med. 2009;234 (10):1166-73.
75. Yang B, Chuang H, Yang K. Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol J. 2009;6(1):141.
76. Kok CC, Phuektes P, Bek E, McMinn PC. Modification of the untranslated regions of human enterovirus 71 impairs growth in a cell-specific manner. J Virol. 2012;86(1):542-52.
77. Lin J-Y, Li M-L, Shih S-R. Far upstream element binding protein 2 interacts with enterovirus 71 internal ribosomal entry site and negatively regulates viral translation. Nucl Acids Res. 2009;37 (1):47-59.
78. Thompson SR, Sarnow P. Enterovirus 71 contains a type I IRES element that functions when eukaryotic initiation factor eIF4G is cleaved. Virology. 2003;315(1):259-66. (Pubitemid 37340067)
79. Lin J-Y, Shih S-R, Pan M, et al. hnRNP A1 interacts with the 5′ untranslated regions of enterovirus 71 and sindbis virus RNA and is required for viral replication. J Virol. 2009;83(12):6106-14.
80. Shih S-R, Stollar V, Li M-L. Host factors in enterovirus 71 replication. J Virol. 2011;85(19):9658-66.
81. Huang P-N, Lin J-Y, Locker N, et al. Far upstream element binding protein 1 binds the internal ribosomal entry site of enterovirus 71 and enhances viral translation and viral growth. Nucleic Acids Res. 2011;39(22):9633-48.
82. Lin J-Y, Chen T-C, Weng K-F, et al. Viral and host proteins involved in picornavirus life cycle. J Biomed Sci. 2009;16 (1):103.
83. Weng K-F, Li M-L, Hung C-T, Shih S-R. Enterovirus 71 3C protease cleaves a novel target CstF-64 and inhibits cellular polyadenylation. PLoS Pathog. 2009;5(9):e1000593.
84. Lee JJ, Seah JBK, Chow VTK, et al. Comparative proteome analyses of host protein expression in response to Enterovirus 71 and Coxsackievirus A16 infections. J Proteome. 2011;74 (10):2018-24.
85. Khong WX, Foo DGW, Trasti SL, et al. Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse model. J Virol. 2011;85(7):3067-76.
86. Chen T-C, Chang H-Y, Lin P-F, et al. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob Agents Chemother. 2009;53(7):2740-7.
87. Bedard KM, Semler BL. Regulation of picornavirus gene expression. Microbes Infect. 2004;6(7):702-13. (Pubitemid 38670552)
88. Pettersson RF, Ambros V, Baltimore D. Identification of a protein linked to nascent poliovirus RNA and to the polyuridylic acid of negative-strand RNA. J Virol. 1978;27(2):357-65. (Pubitemid 8382277)
89. Schwartz M, Chen J, Lee W-M, et al. Alternate, virus-induced membrane rearrangements support positive-strand RNA virus genome replication. Proc Natl Acad Sci U S A. 2004;101 (31):11263-8. (Pubitemid 39038335)
90. Huang S-C, Chang C-L, Wang P-S, et al. Enterovirus 71-induced autophagy detected in vitro and in vivo promotes viral replication. J Med Virol. 2009;81(7):1241-52.
91. Castro C, Arnold JJ, Cameron CE. Incorporation fidelity of the viral RNA-dependent RNA polymerase: A kinetic, thermodynamic and structural perspective. Virus Res. 2005;107(2):141-9. (Pubitemid 40093087)
92. Pfeiffer JK, Kirkegaard K. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog. 2005;1(2):e11.
93. Yi L, Lu J, Kung H-F, He M-L. The virology and developments toward control of human enterovirus 71. Crit Rev Microbiol. 2011;37(4):313-27.
94. Lal SK, Kumar P, Yeo WM, et al. The VP1 protein of human enterovirus 71 self-Associates via an interaction domain spanning amino acids 66-297. J Med Virol. 2006;78 (5):582-90.
95. Shih S-R, Weng K-F, Stollar V, Li M-L. Viral protein synthesis is required for enterovirus 71 to induce apoptosis in human glioblastoma cells. J Neurovirol. 2008;14(1):53-61. (Pubitemid 351314973)
96. Kuo R-L, Kung S-H, Hsu Y-Y, Liu W-T. Infection with enterovirus 71 or expression of its 2A protease induces apoptotic cell death. J Gen Virol. 2002;83(6):1367-76. (Pubitemid 34591331)
97. Li M-L, Hsu T-A, Chen T-C, et al. The 3C protease activity of enterovirus 71 induces human neural cell apoptosis. Virology. 2002;293(2):386-95.
98. Ho H-Y, Cheng M-L, Weng S-F, et al. Glucose-6-phosphate dehydrogenase deficiency enhances enterovirus 71 infection. J Gen Virol. 2008;89(9):2080-9.
99. Lu J, Yi L, Zhao J, et al. Enterovirus 71 disrupts interferon signaling by reducing the interferon receptor I. J. Virol. 2012, in press. 100. Lei X, Sun Z, Liu X, et al. Cleavage of the adaptor protein TRIF by enterovirus 71 3C inhibits antiviral responses mediated by tolllike receptor 3. J Virol. 2011;85(17):8811-8.
100. Lei X, Liu X, Ma Y, et al. The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses. J Virol. 2010;84(16):8051-61.
101. Chang H-W, Liu C-C, Lin M-H, et al. Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates. J Virol Methods. 2011;173(2):189-95.
102. Hung H-C, Wang H-C, Shih S-R, et al. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J Infect Dis. 2011;203(12):1784-90.
103. Lin T-Y, Hsia S-H, Huang Y-C, et al. Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis. 2003;36(3):269-74. (Pubitemid 36169660)
104. Wang S-M, Lei H-Y, Huang K-J, et al. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis. 2003;188(4):564-70. (Pubitemid 37011809)
105. Yang J, Zhao N, Su N-L, et al. Association of interleukin 10 and interferon gamma gene polymorphisms with enterovirus 71 encephalitis in patients with hand, foot and mouth disease. Scand J Infect Dis. 2012, Epub ahead of print:1-5.
106. Lin TY, Chang LY, Huang YC, et al. Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: Implications for early recognition and therapy. Acta Paediatr. 2002;91 (6):632-5.
107. Leong WF, Chow VTK. Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal differential cellular gene expression in response to enterovirus 71 infection. Cell Microbiol. 2006;8(4):565-80. (Pubitemid 43372736)
108. Tung W-H, Hsieh H-L, Yang C-M. Enterovirus 71 induces COX-2 expression via MAPKs, NF-[kappa]B, and AP-1 in SK-N-SH cells: role of PGE2 in viral replication. Cell Signal. 2010;22 (2):234-46.
109. Ghukasyan V, Hsu Y-Y, Kung S-H, Kao F-J. Application of fluorescence resonance energy transfer resolved by fluorescence lifetime imaging microscopy for the detection of enterovirus 71 infection in cells. J Biomed Opt. 2007;12(2):024016.
110. Arita M, Nagata N, Iwata N, et al. An attenuated strain of enterovirus 71 belonging to genotype A showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol. 2007;81(17):9386-95. 112. 9. (Pubitemid 47311481)
111. Zhang Y, Cui W, Liu L, et al. Pathogenesis study of enterovirus 71 infection in rhesus monkeys. Lab Invest. 2011;91(9):1337-50.
112. The results of this pathogenesis study in rhesus monkeys suggest that rhesus monkeys are will become an important animal model for HEV71 infection. Following infection via the intravenous and intratracheal routes, HEV71 was detected in the lungs and CNS of the monkeys. In general, the pathogenesis of HEV71 in the rhesus monkeys was more analogous to human disease than cynomolgus monkeys.
113. Chang G-H, Lin L, Luo Y-J, et al. Sequence analysis of six enterovirus 71 strains with different virulences in humans. Virus Res. 2010;151(1):66-73. In this study of six HEV71 clinical isolates, three of the strains were naturally mousevirulent. Pathogenicity in mice did not correlate with human pathogenicity.
114. Yeh M-T, Wang S-W, Yu C-K, et al. A single nucleotide in stem loop II of 5′-untranslated region contributes to virulence of enterovirus 71 in mice. PLoS One. 2011;6(11):e27082.
115. Khong WX, Yan B, Yeo H, et al. A non mouse-Adapted enterovirus 71 (EV71) strain exhibits neurotropism causing neurological manifestations in a novel mouse model of EV71 infection. J Virol. 2011;86(4):2121-31. This study reports that non-mouse adapted HEV71 is able to infect 2-week-old AG129 mice, which lack type I and II interferon receptors.
116. Kung Y-H, Huang S-W, Kuo P-H, et al. Introduction of a strong temperature-sensitive phenotype into enterovirus by altering an amino acid of virus 3D polymerase. Virology. 2010;396(1):1-9.
117. Wang W, Duo J, Liu J, et al. A mouse muscle-Adapted enterovirus 71 strain with increased virulence in mice. Microbes Infect. 2011;13(10):862-70.
118. Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother. 1999;43(9):2109-15. (Pubitemid 29421185)
119. Zhang G, Zhou F, Gu B, et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012, Epub ahead of print:1-11. In this study, Pleconaril was shown to reduce the morbidity and mortality HEV71 infection in one-day-old mice.
120. Lu G, Qi J, Chen Z, et al. Enterovirus 71 and coxsackievirus A16 3C proteases: Ainding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol. 2011;85 (19):10319-31.
121. Wang J, Fan T, Yao X, et al. Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues. J Virol. 2011;85(19):10021-30.
122. Kuo C-J, Shie J-J, Fang J-M, et al. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg Med Chem. 2008;16(15):7388-98.
123. Thibaut HJ, De Palma AM, Neyts J. Combating enterovirus replication: State-of-The-Art on antiviral research. Biochem Pharmacol. 2012;83(2):185-92.
124. Yi L, He Y, Chen Y, et al. Potent inhibition of human enterovirus 71 replication by type I interferon subtypes. Antivir Ther. 2011;16(1):51-8.
125. Falah N, Violot S, Décimo D, et al. Ex vivo and in vivo inhibition of human rhinovirus replication by a new pseudosubstrate of viral 2A protease. J Virol. 2012;86(2):691-704.
126. Li Z-H, Li C-M, Ling P, et al. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis. 2008;197(6):854-7. (Pubitemid 351417008)
127. AritaM,Wakita T, ShimizuH. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J Gen Virol. 2009;90(8):1869-79.
128. Tsai F-J, Lin C-W, Lai C-C, et al. Kaempferol inhibits enterovirus 71 replication and internal ribosome entry site (IRES) activity through FUBP and HNRP proteins. Food Chem. 2011;128(2):312-22.
129. Zhu Q-C, Wang Y, Liu Y-P, et al. Inhibition of enterovirus 71 replication by chrysosplenetin and penduletin. Eur J Pharm Sci. 2011;44(3):392-8.
130. Wu Z, Yang F, Zhao R, et al. Identification of small interfering RNAs which inhibit the replication of several Enterovirus 71 strains in China. J Virol Methods. 2009;159(2):233-8.
131. Tan EL, Tan TMC, Chow VTK, Poh CL. Inhibition of enterovirus 71 in virus-infected mice by RNA interference. Mol Ther. 2007;15(11):1931-8. (Pubitemid 350011732)
132. Lim XF, Jia Q, Khong WX, et al. Characterization of an isotypedependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS One. 2012;7(1):e29751.
133. Han J-F, Cao R-Y, Deng Y-Q, et al. Antibody dependent enhancement infection of Enterovirus 71 in vitro and in vivo. Virol J. 2011;8(1):106.
134. Cao R, Han J, Deng Y, et al. Presence of high titer neutralizing antibodies against enterovirus 71 in intravenous immunoglobulin manufactured from Chinese donors. Clin Infect Dis. 2010;50 (1):125-6.
135. Lee BY, Wateska AR, Bailey RR, et al. Forecasting the economic value of an enterovirus 71 (EV71) vaccine. Vaccine. 2010;28 (49):7731-6.
136. Jia H, Carey K. Chinese vaccine developers gain WHO imprimatur. Nat Biotechnol. 2011;29(6):471-2.
137. Sinovac developing vaccine for hand, foot, and mouth disease. Worldw Biotech. 2008, Nov 1.
138. Ong KC, Devi S, Cardosa MJ, Wong KT. Formaldehydeinactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol. 2010;84 (1):661-5.
139. Romanowski B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccin Immunother. 2011;7 (2):161-9.
140. Chung Y-C, Ho M-S, Wu J-C, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26 (15):1855-62.
141. Chung C-Y, Chen C-Y, Lin S-Y, et al. Enterovirus 71 virus-like particle vaccine: Improved production conditions for enhanced yield. Vaccine. 2010;28(43):6951-7.
142. Liu JN, Wang W, Duo JY, et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine. 2010;28(46):7444-51.
143. Ch'ng W-C, Stanbridge EJ, Ong K-C, et al. Partial protection against enterovirus 71 (EV71) infection in a mouse model immunized with recombinant Newcastle disease virus capsids displaying the EV71 VP1 fragment. J Med Virol. 2011;83 (10):1783-91.
144. Chen H-F, Chang M-H, Chiang B-L, Jeng S-T. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine. 2006;24(15):2944-51.
145. Tung W, Bakar S, Sekawi Z, Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther. 2007;5(1):6.
146. Gao F, Wang Y-P, Mao Q-Y, et al. Enterovirus 71 viral capsid protein linear epitopes: Identification and characterization. Virol J. 2012;9(1):26.
147. Vignuzzi M, Wendt E, Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med. 2008;14 (2):154-61. (Pubitemid 351214560)
148. Barnes D, Kunitomi M, Vignuzzi M, et al. Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe. 2008;4 (3):239-48.
149. Vadim IA. Vaccine-derived polioviruses. Biologicals. 2006;34 (2):103-8.
150. Jiang H, Weng L, Zhang N, et al. Biochemical characterization of enterovirus 71 3D RNA polymerase. Biochim Biophys Acta-Gene Regul Mech. 2011;1809(3):211-9.
151. Mueller S, Papamichail D, Coleman JR, et al. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J Virol. 2006;80(19):9687-96. (Pubitemid 44435643)